Sinopharm CNBG COVID-19 vaccine

Last updated

Sinopharm CNBG COVID-19 vaccine
Vaccine description
Target SARS-CoV-2
Vaccine type Protein subunit
Clinical data
Routes of
administration 		Intramuscular
Legal status
Legal status
Identifiers
CAS Number

Sinopharm NVSI COVID-19 vaccine, also known as mutI-tri-RBD or NVSI-06-08, is a COVID-19 vaccine developed by National Vaccine & Serum Institute (NVSI, 中生研究院), a subsidiary of CNBG of Sinopharm. [2] [3]

They claim to be the world's first "second generation broadly protective" recombination protein subunit vaccine, i.e. by combining three heterogeneous antigens into one single trimer RBD protein (突变集成三聚化RBD, mutI-tri-RBD). [4] It's based on the original, and the Beta (K417N/E484K/N501Y) and Kappa (L452R/E484K) variants. [5]

References

  1. ↑ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
  2. ↑ "Emergency use of Sinopharm's new CNBG protein vaccine approved in UAE". Gulf News . 27 December 2021. Retrieved 27 December 2021.
  3. ↑ "China's new recombinant COVID-19 vaccine starts human tests". Xinhua. 25 April 2021. Retrieved 5 May 2021.
  4. ↑ 國藥集團：二代重組蛋白新冠疫苗保護效果良好
  5. ↑ Kaabi NA, Yang YK, Du LF, Xu K, Shao S, Liang Y, et al. (June 2022). "Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial". Nature Communications. 13 (1): 3654. Bibcode:2022NatCo..13.3654K. doi:10.1038/s41467-022-31379-0. PMC   9237056 . PMID   35760812.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.